Oric Pharmaceuticals price target lowered to $25 from $27 at Baird

Baird analyst Colleen Kusy lowered the firm’s price target on Oric Pharmaceuticals to $25 from $27 and keeps an Outperform rating on the shares. The firm noted they reported Q423 results and notably, timelines for its lead two programs remain on track and Baird remains particularly bullish on the ORIC-944 opportunity, and so reiterate their rating and adjust our price target to reflect the recent capital raise.